432 related articles for article (PubMed ID: 30398481)
1. Sodium zirconium cyclosilicate: a new potassium binder for the treatment of hyperkalemia.
Cases A; Gorriz JL
Drugs Today (Barc); 2018 Oct; 54(10):601-613. PubMed ID: 30398481
[TBL] [Abstract][Full Text] [Related]
2. Effects and Safety of a Novel Oral Potassium-Lowering Drug-Sodium Zirconium Cyclosilicate for the Treatment of Hyperkalemia: a Systematic Review and Meta-Analysis.
Zhang Y; Xu R; Wang F; Liu Y; Xu J; Zhao N; Cheng F; Long L; Jia J; Lin S
Cardiovasc Drugs Ther; 2021 Oct; 35(5):1057-1066. PubMed ID: 33459923
[TBL] [Abstract][Full Text] [Related]
3. Sodium Zirconium Cyclosilicate among Individuals with Hyperkalemia: A 12-Month Phase 3 Study.
Spinowitz BS; Fishbane S; Pergola PE; Roger SD; Lerma EV; Butler J; von Haehling S; Adler SH; Zhao J; Singh B; Lavin PT; McCullough PA; Kosiborod M; Packham DK;
Clin J Am Soc Nephrol; 2019 Jun; 14(6):798-809. PubMed ID: 31110051
[TBL] [Abstract][Full Text] [Related]
4. An evaluation of sodium zirconium cyclosilicate as a treatment option for hyperkalemia.
Takkar C; Nassar T; Qunibi W
Expert Opin Pharmacother; 2021 Jan; 22(1):19-28. PubMed ID: 32892634
[TBL] [Abstract][Full Text] [Related]
5. New Therapeutic Approaches for the Treatment of Hyperkalemia in Patients Treated with Renin-Angiotensin-Aldosterone System Inhibitors.
Tamargo J; Caballero R; Delpón E
Cardiovasc Drugs Ther; 2018 Feb; 32(1):99-119. PubMed ID: 29372448
[TBL] [Abstract][Full Text] [Related]
6. Sodium zirconium cyclosilicate reconciles management of hyperkalemia and continuity of renin-angiotensin-aldosterone system inhibitors: a retrospective observational study.
Kimura W; Minatoguchi S; Mizuno T; Koide S; Hayashi H; Hasegawa M; Inaguma D; Tsuboi N
J Nephrol; 2024 Jan; 37(1):171-179. PubMed ID: 37608241
[TBL] [Abstract][Full Text] [Related]
7. Sodium zirconium cyclosilicate for the management of chronic hyperkalemia in kidney disease, a novel agent.
Rastogi A; Hanna RM; Mkrttchyan A; Khalid M; Yaqoob S; Shaffer K; Dhawan P; Nobakht N; Kamgar M; Goshtaseb R; Sarmosyan K; Gnarini M; Wassef O; Lerma E
Expert Rev Clin Pharmacol; 2021 Sep; 14(9):1055-1064. PubMed ID: 34227913
[TBL] [Abstract][Full Text] [Related]
8. Pharmacodynamics and pharmacokinetics of sodium zirconium cyclosilicate [ZS-9] in the treatment of hyperkalemia.
Packham DK; Kosiborod M
Expert Opin Drug Metab Toxicol; 2016 May; 12(5):567-73. PubMed ID: 26998854
[TBL] [Abstract][Full Text] [Related]
9. Correction of serum potassium with sodium zirconium cyclosilicate in Japanese patients with hyperkalemia: a randomized, dose-response, phase 2/3 study.
Kashihara N; Nishio T; Osonoi T; Saka Y; Imasawa T; Ohtake T; Mizuno H; Shibagaki Y; Kim H; Yajima T; Sarai N
Clin Exp Nephrol; 2020 Dec; 24(12):1144-1153. PubMed ID: 32779057
[TBL] [Abstract][Full Text] [Related]
10. Potassium-Binding Agents to Facilitate Renin-Angiotensin-Aldosterone System Inhibitor Therapy.
Schaefer JA; Gales MA
Ann Pharmacother; 2016 Jun; 50(6):502-10. PubMed ID: 27009290
[TBL] [Abstract][Full Text] [Related]
11. Sodium zirconium cyclosilicate (ZS-9) for the treatment of hyperkalemia.
Rafique Z; Peacock WF; LoVecchio F; Levy PD
Expert Opin Pharmacother; 2015; 16(11):1727-34. PubMed ID: 26159448
[TBL] [Abstract][Full Text] [Related]
12. Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial.
Kosiborod M; Rasmussen HS; Lavin P; Qunibi WY; Spinowitz B; Packham D; Roger SD; Yang A; Lerma E; Singh B
JAMA; 2014 Dec; 312(21):2223-33. PubMed ID: 25402495
[TBL] [Abstract][Full Text] [Related]
13. A Phase 3b, Randomized, Double-Blind, Placebo-Controlled Study of Sodium Zirconium Cyclosilicate for Reducing the Incidence of Predialysis Hyperkalemia.
Fishbane S; Ford M; Fukagawa M; McCafferty K; Rastogi A; Spinowitz B; Staroselskiy K; Vishnevskiy K; Lisovskaja V; Al-Shurbaji A; Guzman N; Bhandari S
J Am Soc Nephrol; 2019 Sep; 30(9):1723-1733. PubMed ID: 31201218
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness analysis of sodium zirconium cyclosilicate for hyperkalemia among patients with chronic kidney disease or heart failure in Kuwait.
Elsisi GH; Mahmoud MMI; Al-Humood K; Al-Yousef A
J Med Econ; 2024; 27(1):253-265. PubMed ID: 38318718
[TBL] [Abstract][Full Text] [Related]
15. Emergency Potassium Normalization Treatment Including Sodium Zirconium Cyclosilicate: A Phase II, Randomized, Double-blind, Placebo-controlled Study (ENERGIZE).
Peacock WF; Rafique Z; Vishnevskiy K; Michelson E; Vishneva E; Zvereva T; Nahra R; Li D; Miller J
Acad Emerg Med; 2020 Jun; 27(6):475-486. PubMed ID: 32149451
[TBL] [Abstract][Full Text] [Related]
16. Potassium Binders for Hyperkalemia in Chronic Kidney Disease-Diet, Renin-Angiotensin-Aldosterone System Inhibitor Therapy, and Hemodialysis.
Palmer BF
Mayo Clin Proc; 2020 Feb; 95(2):339-354. PubMed ID: 31668450
[TBL] [Abstract][Full Text] [Related]
17. Impact of Sodium Zirconium Cyclosilicate Plus Renin-Angiotensin-Aldosterone System Inhibitor Therapy on Short-Term Medical Costs in Hyperkalemia: OPTIMIZE II Real-World Study.
Dwyer JP; Agiro A; Desai P; Oluwatosin Y
Adv Ther; 2023 Nov; 40(11):4777-4791. PubMed ID: 37606716
[TBL] [Abstract][Full Text] [Related]
18. Single Dose of Sodium Zirconium Cyclosilicate Versus Sodium Polystyrene Sulfonate in Hospitalized Patients With Hyperkalemia.
Yoo N; Song YB; Dubinsky I; Altshuler J
Ann Pharmacother; 2023 Sep; 57(9):1044-1052. PubMed ID: 36637028
[TBL] [Abstract][Full Text] [Related]
19. Combination Therapy Using Sodium Zirconium Cyclosilicate and a Mineralocorticoid Receptor Antagonist in Patients with Heart Failure and Hyperkalemia.
Imamura T; Oshima A; Narang N; Ushijima R; Ueno Y; Ueno H; Kinugawa K
Intern Med; 2021; 60(13):2093-2095. PubMed ID: 34193775
[TBL] [Abstract][Full Text] [Related]
20. A phase 3 multicenter open-label maintenance study to investigate the long-term safety of sodium zirconium cyclosilicate in Japanese subjects with hyperkalemia.
Kashihara N; Yamasaki Y; Osonoi T; Harada H; Shibagaki Y; Zhao J; Kim H; Yajima T; Sarai N
Clin Exp Nephrol; 2021 Feb; 25(2):140-149. PubMed ID: 33098526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
